Literature DB >> 26606870

Persistent occurrence of serogroup Y/sequence type (ST)-23 complex invasive meningococcal disease among patients aged five to 14 years, Italy, 2007 to 2013.

Cecilia Fazio1, Arianna Neri, Giovanna Renna, Paola Vacca, Raffaele Antonetti, Anna Maria Barbui, Laura Daprai, Paolo Lanzafame, Lucia Rossi, Iolanda Santino, Carlo Tascini, Caterina Vocale, Paola Stefanelli.   

Abstract

In Italy, the incidence of invasive meningococcal disease (IMD) has remained stable since 2007 (around 0.3 cases/100,000 inhabitants). However, as reported for other European countries, an increase of serogroup Y Neisseria meningitidis has been observed. In this study we report IMD cases from 2007 to 2013 in Italy and investigate the clinical and epidemiological features of cases affected by serogroup Y. Molecular characteristics of serogroup Y strains are also described. During the study period, the proportion of IMD cases due to serogroup Y increased, ranging from 2% in 2007 to 17% in 2013 (odds ratio (OR): 8.8), whereby the five to 14 years age group was mostly affected (p < 0.001). Overall 81 serogroup Y IMD cases were identified, with a median age of 18 years, ranging from three months to 84 years. Of the 81 respective patient samples, 56 were further subject to molecular typing. The sequence type (ST)-23 complex (clonal complex (cc)23) was predominant among serogroup Y meningococci (54/56 samples), and included nine different STs. Presumably, ST-23 was the founding genotype, with all the other STs presenting as single-locus variants. All cc23 isolates analysed harboured mutations in the lpxL1 gene; however, no associations among lpxL1 mutations, ST and age group were identified. Overall, these findings generate scientific evidence for the use of the quadrivalent meningococcal conjugate vaccine in the five to 14 years age group.

Entities:  

Keywords:  ST-23 complex; meningococcus; serogroup Y

Mesh:

Substances:

Year:  2015        PMID: 26606870     DOI: 10.2807/1560-7917.ES.2015.20.45.30061

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  6 in total

Review 1.  Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review.

Authors:  Gary S Marshall; Jaime Fergie; Jessica Presa; Paula Peyrani
Journal:  Infect Dis Ther       Date:  2022-03-31

2.  Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines.

Authors:  Lidia Serra; Markus Knuf; Federico Martinón-Torres; Kevin Yi; Jamie Findlow
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

3.  Genomic analysis of Neisseria meningitidis carriage isolates during an outbreak of serogroup C clonal complex 11, Tuscany, Italy.

Authors:  Luigina Ambrosio; Arianna Neri; Cecilia Fazio; Gian Maria Rossolini; Paola Vacca; Eleonora Riccobono; Fabio Voller; Alessandro Miglietta; Paola Stefanelli
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

4.  Cocirculation of Hajj and non-Hajj strains among serogroup W meningococci in Italy, 2000 to 2016.

Authors:  Cecilia Fazio; Arianna Neri; Paola Vacca; Andrea Ciammaruconi; Milena Arghittu; Anna Maria Barbui; Caterina Vocale; Paola Bernaschi; Patrizia Isola; Irene Alessandra Galanti; Antonella Mencacci; Rosella De Nittis; Maria Chironna; Anna Giammanco; Elisabetta Pagani; Alessandro Bisbano; Paola Stefanelli
Journal:  Euro Surveill       Date:  2019-01

5.  Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy.

Authors:  Cecilia Fazio; Alessia Biolchi; Arianna Neri; Sara Tomei; Paola Vacca; Luigina Ambrosio; Annapina Palmieri; Elena Mori; Rita La Gaetana; Mariagrazia Pizza; Marzia Monica Giuliani; Laura Serino; Paola Stefanelli
Journal:  Hum Vaccin Immunother       Date:  2021-01-31       Impact factor: 3.452

6.  Whole genome sequencing of Neisseria meningitidis Y isolates collected in the Czech Republic in 1993-2018.

Authors:  Michal Honskus; Zuzana Okonji; Martin Musilek; Pavla Krizova
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.